3721 Valley Centre Drive
Tel: 888-969-RTRX (7879)
At Retrophin, our number one priority will always be the patients we serve - they are “why” we come to work each day. Our Why is ingrained into our culture and is paramount to “what” we do every day and “how” we do it to achieve our mission of identifying, developing and delivering life-changing therapies to people living with rare disease. By working hard, supporting our team members and living our values of Accountability, Entrepreneurial Spirit, Integrity, Patient Focus, Scientific Excellence and Teamwork, we strive to help our organization succeed and pursue our vision - to become a preeminent, global and fully-integrated biopharmaceutical company within the rare disease community that is dedicated to giving patients a chance and providing hope.
Our pipeline features late-stage development programs targeting rare diseases with significant unmet medical needs including sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. In partnership with leaders in patient advocacy and government research, we are also working to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, rare conditions with no approved treatment options. Our R&D efforts are supported by revenues from our four commercial products Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin) and THIOLA EC™ (tiopronin) delayed-release tablets.
Through our portfolio of approved products and promising pipeline focused on hepatology, nephrology and neurology, we strive to help people achieve the best possible outcomes today and tomorrow. But most importantly, it is the commitment of our experienced, knowledgeable and compassionate team members, who put patients at the center of everything they do, that truly matters.
Stock Symbol: RTRX
Stock Exchange: NASDAQ
178 articles with Retrophin
Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from the Phase 2 DUET Study examining the impact of sparsentan on quality of life in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN) Kidney Week 2019
Retrophin, Inc. announced the appointment of Peter Heerma as chief commercial officer, effective immediately.
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the 2019 Cantor Global Healthcare Conference in New York City on Thursday, October 3, 2019 at 5:20 p.m. ET.
8/26/2019Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN
Retrophin, Inc. announced that the Phase 3 FORT Study evaluating the safety and efficacy of fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration did not meet its primary endpoint and did not demonstrate a difference between treatment groups.
Shares of Retrophin have plunged more than 24% in premarket trading after the San Diego-based company announced its Phase III treatment for pantothenate kinase-associated neurodegeneration did not stack up against placebo.
Retrophin, Inc. reported its second quarter 2019 financial results and provided a corporate update.
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston on Wednesday, August 7, 2019 at 8:30 a.m. ET.
Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria
Retrophin, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatment of cystinuria, a rare inherited disorder that causes a buildup of cystine levels in the urine resulting in the formation of recurring cystine kidney stones.
Retrophin, Inc. announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the U.S. financial markets.
Retrophin, based in San Diego, announced that the U.S. Food and Drug Administration (FDA) had given its 100 mg and 300 mg tablets of Thiola EC (tiopronin) the thumbs-up to treat cystinuria.
July looks to be a quiet month for the U.S. Food and Drug Administration (FDA), and it sure looks like the agency is trying to get a lot of work done before the July 4 holiday. Here’s a look at the many approvals scheduled for this week.
Two weeks after filing a lawsuit against his former company from prison, Martin Shkreli has reached a settlement with Retrophin.
Retrophin Announces Cooperative Research and Development Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome
Retrophin, Inc. announced that it has entered into a three-way Cooperative Research and Development Agreement with the National Institutes of Health’s National Center for Advancing Translational Sciences and patient advocacy foundation Alagille Syndrome Alliance to collaborate on research efforts aimed at the identification and development of potentially novel therapeutics for Alagille syndrome.
Retrophin, Inc. announced that Company management will present at the following upcoming investor conferences in June
Ms. Poole brings more than 25 years of biopharmaceutical product development and manufacturing experience to Retrophin
Retrophin, Inc. reported its first quarter 2019 financial results and provided a corporate update.
Retrophin, Inc. announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the U.S. financial markets.
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the following upcoming investor conferences in March
Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers
Retrophin, Inc. joins the National Organization for Rare Disorders, the European Organisation for Rare Diseases, and others worldwide to recognize Rare Disease Day® 2019.